Instead of celebrating VIVUS' (VVUS) drug launch last quarter, shareholders were shocked to hear the company report thin sales and see the stock's share price cut by a whopping 20%. The company is set to report its fourth-quarter results -- the first full quarter featuring Qsymia sales -- on Feb. 25, and investors are wondering whether this biotech can regain its momentum. Should they continue tracking sales, or are there other issues that deserve equal attention? Health-care analyst Max Macaluso dives into this topic in the following video.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.